KTE-C19

October 17, 2016

Kite Appoints European Head to Prepare for Potential Launch of Lead Lymphoma Therapy

News

Kite Pharma has appointed Chris Nowers as its new Head of Europe to oversee European commercial operations, raise awareness of Kite’s pipeline portfolio of CAR and T-cell receptor (TCR) therapy ... Read more

October 12, 2016October 12, 2016

Phase 1b/2 Trial of Combo Therapy for Diffuse Large B-cell Lymphoma Gets Underway

News

Kite Pharma has enrolled the first patient in a Phase 1b/2 study evaluating the safety and efficacy of KTE-C19, a CAR T-cell therapy, in combination with Genentech’s anti-PD-L1 immunotherapy atezolizumab, for the ... Read more

September 29, 2016

Interim Analysis Shows Promise for KTE-C19 in Treating Aggressive Non-Hodgkin Lymphomas

News

Kite Pharma recently reported positive data from an interim analysis of ZUMA-1, a clinical trial assessing the safety and efficacy of KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma (DLBCL). KTE-C19 is an ... Read more

June 2, 2016June 2, 2016

Kite Pharma Moves Forward with KTE-C19 for Chemorefractory Diffuse Large B-Cell Lymphoma

News

Kite Pharma, Inc., a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, is moving forward with the company’s KTE-C19, an experimental therapy currently in a pivotal trial ... Read more

May 26, 2016May 26, 2016

Therapeutic Potential of Genetically Engineered T Cells for Non-Hodgkin’s Lymphoma Patients Addressed in Phase 2 Trial

News

A novel cellular immunotherapy in which patients’ T cells are engineered to express the chimeric antigen receptor (CAR) for CD19, a cell surface protein expressed on lymphoma cells, is being ... Read more

February 29, 2016

Last Week’s Hot Topic on Lymphoma

Last week’s hot topic on Lymphoma was about the Lymphoma and Leukemia Clinical Trials of Immunotherapy Drug to Treat Resistant Cancers Now Recruiting Patients written by Margarida Azevedo. The article is centered around the ... Read more

February 25, 2016February 25, 2016

Lymphoma and Leukemia Clinical Trials of Immunotherapy Drug to Treat Resistant Cancers Now Recruiting Patients

News

Three new clinical trials aim to assess the safety and efficacy of a new cancer immunotherapy treatment, KTE-C19, in patients with three types of treatment-resistant blood cancers — refractory aggressive ... Read more

August 18, 2015August 23, 2016

Kite Pharma Updates KTE-C19 Clinical Trial progress, On Track To Advance To Pivotal Phase 2

News

Santa Monica, California, based Kite Pharma, Inc. (Kite) on Monday provided in a Conference Call and Webcast, an updated progress report from the company’s ongoing Phase 1/2 clinical trial of ... Read more